Psilocybin Shows Initial Efficacy in Treatment-Resistant Depression

A British NHS clinical trial involving 60 participants has demonstrated that psilocybin, a naturally occurring psychedelic compound, shows promise in treating treatment-resistant depression—cases where standard antidepressants have failed. Participants receiving psilocybin-assisted therapy experienced significant improvements compared to placebo controls. However, researchers emphasize the need for larger confirmatory studies before clinical recommendations can be made. This finding represents an important development in psychiatric research, as treatment-resistant depression affects millions globally and leaves patients with limited therapeutic options. The results suggest psilocybin may offer a novel mechanism of action for severe depressive disorders.